A 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma
Phase of Trial: Phase III
Latest Information Update: 23 Oct 2019
Price : $35 *
At a glance
- Drugs Fevipiprant (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms ZEAL
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 11 Oct 2019 Status changed from active, no longer recruiting to completed.
- 26 Jul 2019 Planned End Date changed from 29 Jul 2019 to 2 Aug 2019.
- 03 Jul 2019 Planned End Date changed from 20 Nov 2019 to 29 Jul 2019.